Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
646
datasets available to search
ShareScore release 0.9.0
Dataset results
646 results for “Clinical data”
Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials
ClinicalTrials.gov study NCT01332448. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"
ClinicalTrials.gov study NCT05495802. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries — Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients
GEO Series GSE241957. Homo sapiens. 88 samples. Type: Other.
Ependymoma subpopulation lineages underlie clinical classification and outcome (microarray data set)
GEO Series GSE125861. Homo sapiens. 69 samples. Type: Expression profiling by array.
Identification of a new gene regulatory circuit involving B cell receptor activated signaling using a combined analysis of experimental, clinical and global gene expression data [timeSeries]
GEO Series GSE71721. Homo sapiens. 33 samples. Type: Expression profiling by array.
Expression data from tumors and adjacent normal tissue from clinical oral cancer patients
GEO Series GSE74530. Homo sapiens. 12 samples. Type: Expression profiling by array.
RNA-seq dataset for Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements
GEO Series GSE98739. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
Integration of genomic and clinical data to predict endometrioid endometrial cancer recurrence
GEO Series GSE216872. Homo sapiens. 61 samples. Type: Expression profiling by high throughput sequencing.
A Low-cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-relevant Subtypes: OriGene Cohort Microarray Data
GEO Series GSE101472. Homo sapiens. 17 samples. Type: Expression profiling by array.
Expression data of clinical Pseudomonas aeruginosa isolates grown in vitro in glucose minimal medium
GEO Series GSE62970. Pseudomonas aeruginosa. 9 samples. Type: Expression profiling by array.
Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
GEO Series GSE59526. Homo sapiens. 18 samples. Type: Expression profiling by array.
Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the NCCR
The goal of this study is to contribute clinical and genomic data from a large institutional cohort of pediatric cancer patients who had tumor genomic profiling between 2013 and 2019 at Dana-Farber/Boston Children's Hospital Cancer and Blood Disorders Center. Clinical data include demographics, diagnosis (classified according to the International Classification of Diseases for Oncology (ICD-O-3.2), stage, and biospecimen associated data. Tumors were sequenced with OncoPanel, a targeted next-generation DNA sequencing panel of up to 447 cancer genes for detection of single-nucleotide variants (SNV), insertions, and deletions, and copy number alterations (CNA), as well as selected intronic regions for up to 60 genes for the detection of structural variants (SV). This dataset includes a patient and sample identifier (GENIE ID) that can be used to link the genomic data included in this dataset to additional longitudinal clinical cancer data on a subset of patients that was submitted to the National Childhood Cancer Registry (NCCR).
Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the NCCR
Open the record for dataset details and reuse information.
Data set from Monasky MM, Micaglio E, Vicedomini G, Locati ET, Ciconte G, Giannelli L, Giordano F, Crisà S, Vecchi M, Borrelli V, Ghiroldi A, D'Imperio S, Di Resta C, Benedetti S, Ferrari M, Santinelli V, Anastasia L, Pappone C. Comparable clinical characteristics in Brugada syndrome patients harboring SCN5A or novel SCN10A variants. Europace. 2019 Oct 1;21(10):1550-1558. doi: 10.1093/europace/euz186. PMID: 31292628.
<p>Data set from Monasky MM, Micaglio E, Vicedomini G, Locati ET, Ciconte G, Giannelli L, Giordano F, Crisà S, Vecchi M, Borrelli V, Ghiroldi A, D'Imperio S, Di Resta C, Benedetti S, Ferrari M, Santinelli V, Anastasia L, Pappone C. Comparable clinical characteristics in Brugada syndrome patients harboring SCN5A or novel SCN10A variants. Europace. 2019 Oct 1;21(10):1550-1558. doi: 10.1093/europace/euz186. PMID: 31292628.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Aims: </strong>The Brugada syndrome (BrS) is an inherited disease associated with an increased risk of sudden cardiac death. Often, the genetic cause remains undetected. Perhaps due at least in part because the NaV1.8 protein is expressed more in both the central and peripheral nervous systems than in the heart, the SCN10A gene is not included in diagnostic arrhythmia/sudden death panels in the vast majority of cardiogenetics centres.</p> <p><strong>Methods and results: </strong>Clinical characteristics were assessed in patients harboring either SCN5A or novel SCN10A variants. Genetic testing was performed using Next Generation Sequencing on genomic DNA. Clinical characteristics, including the arrhythmogenic substrate, in BrS patients harboring novel SCN10A variants and SCN5A variants are comparable. Clinical characteristics, including gender, age, personal history of cardiac arrest/syncope, spontaneous BrS electrocardiogram pattern, family history of sudden death, and arrhythmic substrate are not significantly different between probands harboring SCN10A or SCN5A variants.</p> <p><strong>Conclusion: </strong>Future studies are warranted to further characterize the role of these specific SCN10A variants.</p> <p> </p>
Data set from De Carlo M, Testa L, Leoncini M, Nicolini E, Varbella F, Cortese B, Ribichini F, Bartorelli AL, Calabria P, Indolfi C, Tomai F, Loi B, Fischietti D, Tarantini G, Bedogni F, Petronio AS. Two-year clinical outcomes of the "Italian diffuse/multivessel disease absorb prospective registry" (IT-DISAPPEARS). Int J Cardiol. 2019 Sep 1;290:21-26. doi: 10.1016/j.ijcard.2019.04.095. Epub 2019 May 3. PMID: 31104821.
<p>Data set from De Carlo M, Testa L, Leoncini M, Nicolini E, Varbella F, Cortese B, Ribichini F, Bartorelli AL, Calabria P, Indolfi C, Tomai F, Loi B, Fischietti D, Tarantini G, Bedogni F, Petronio AS. Two-year clinical outcomes of the "Italian diffuse/multivessel disease absorb prospective registry" (IT-DISAPPEARS). Int J Cardiol. 2019 Sep 1;290:21-26. doi: 10.1016/j.ijcard.2019.04.095. Epub 2019 May 3. PMID: 31104821.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Background: </strong>Large prospective studies on the use of bioresorbable vascular scaffolds (BVS) for diffuse coronary artery disease are lacking. IT DISAPPEARS is a large multicentre prospective registry investigating the short and long-term outcomes of everolimus-eluting BVS in patients with long coronary lesions and/or multivessel coronary artery disease (ClinicalTrials.gov: <a href="http://clinicaltrials.gov/show/NCT02004730">NCT02004730</a>). We hereby report the 2-year outcomes of the registry.</p> <p><strong>Methods: </strong>We enrolled 1002 patients with complex lesions undergoing implantation of 2040 BVS with a prespecified technique including predilation, correct sizing, and postdilation with non-compliant balloons. The primary endpoint was the rate of device-oriented composite endpoint (DOCE), consisting of cardiac death, target vessel-related myocardial infarction (MI), and ischaemia-driven target lesion revascularization (TLR). Secondary endpoints included: 1) patient-oriented composite endpoint (POCE), consisting of all-cause mortality, all infarctions and all revascularisations; 2) definite/probable scaffold thrombosis.</p> <p><strong>Results: </strong>Clinical presentation was an acute coronary syndrome in 59.8% of patients. Total BVS length implanted was 47 ± 22 mm. Postdilation of all scaffolds per patient was performed in 96.8%, while optimal implantation as per study guidelines was applied in 71.4%. Through 2-year follow-up, DOCE occurred in 9.5% of patients (cardiac death 0.6%, target vessel-related MI 5.3%, TLR 6.6%). The rate of POCE was 16.6% and of scaffold thrombosis 1.1%. Female gender, total length of coronary lesions, treatment of bifurcation lesions and use of 2.5 mm scaffolds were independent predictors of DOCE.</p> <p><strong>Conclusions: </strong>The 2-year results of IT-DISAPPEARS show that BVS may yield acceptable clinical outcomes in patients with complex coronary lesions when the implantation technique is appropriate.</p> <p> </p>
Data set from Ciconte G, Santinelli V, Vicedomini G, Borrelli V, Monasky MM, Micaglio E, Giannelli L, Negro G, Giordano F, Mecarocci V, Mazza BC, Locati E, Anastasia L, Calovic Z, Pappone C. Non-invasive assessment of the arrhythmogenic substrate in Brugada syndrome using signal-averaged electrocardiogram: clinical implications from a prospective clinical trial. Europace. 2019 Dec 1;21(12):1900-1910. doi: 10.1093/europace/euz295. PMID: 31647530.
<p>Data set from Ciconte G, Santinelli V, Vicedomini G, Borrelli V, Monasky MM, Micaglio E, Giannelli L, Negro G, Giordano F, Mecarocci V, Mazza BC, Locati E, Anastasia L, Calovic Z, Pappone C. Non-invasive assessment of the arrhythmogenic substrate in Brugada syndrome using signal-averaged electrocardiogram: clinical implications from a prospective clinical trial. Europace. 2019 Dec 1;21(12):1900-1910. doi: 10.1093/europace/euz295. PMID: 31647530.</p> <p> </p> <p>This is the abstract:</p> <p><strong>Aims: </strong> Brugada syndrome (BrS) represents a major cause of sudden cardiac death in young individuals. The risk stratification to forecast future life-threatening events is still controversial. Non-invasive assessment of late potentials (LPs) has been proposed as a risk stratification tool. However, their nature in BrS is still undetermined. The purpose of this study is to assess the electrophysiological determinants of non-invasive LPs.</p> <p><strong>Methods and results: </strong> Two hundred and fifty consecutive patients with (Group 1, n = 96) and without (Group 2, n = 154) BrS-related symptoms were prospectively enrolled in the registry. Signal-averaged electrocardiogram (SAECG) was performed in all subjects before undergoing epicardial mapping. Group 1 patients exhibited larger arrhythmogenic substrates (AS; 5.8 ± 2.8 vs. 2.6 ± 2.1 cm2, P < 0.001) with more delayed potentials (220.4 ± 46.0 vs. 186.7 ± 42.3 ms, P < 0.001). Late potentials were present in 82/96 (85.4%) Group 1 and in 31/154 (20.1%) Group 2 individuals (P < 0.001). Patients exhibiting LPs had more frequently a spontaneous Type 1 pattern (30.1% vs. 10.9%, P < 0.001), SCN5A mutation (34.5% vs. 21.2%, P = 0.02), and exhibited a larger AS with longer potentials (5.8 ± 2.7 vs. 2.2 ± 1.7 cm2; 231.2 ± 37.3 vs. 213.8 ± 39.0 ms; P < 0.001, respectively). Arrhythmogenic substrate dimension was the strongest predictor of the presence of LPs (odds ratio 1.9; P < 0.001). An AS area of at least 3.5 cm2 identified patients with LPs (area under the curve 0.88, 95% confidence interval 0.843-0.931; P < 0.001) with a sensitivity of 86%, specificity 88%, positive predictive value 85%, and negative predictive value 89%.</p> <p><strong>Conclusion: </strong> The results of this study support the role of the epicardial AS as an electrophysiological determinant of non-invasive LPs, which may serve as a tool in the non-invasive assessment of the BrS substrate, as SAECG-LPs could be considered an expression of the abnormal epicardial electrical activity.</p> <p>ClinicalTrials.gov number (<a href="http://clinicaltrials.gov/show/NCT02641431">NCT02641431</a>; <a href="http://clinicaltrials.gov/show/NCT03106701">NCT03106701</a>).</p> <p> </p>
Deidentified Data for Clinical Trial and Clinical Evidence
<p>The data are the clinical evidence for the existence of SARS-CoV-2 "vaccination" poisoning and PCR tests cannot test "vaccinated" SARS-CoV-2 viral infections. The hospital system in PRC changed the lower threshold of basophil indicators in blood tests to hide the clinical evidence indicators from the patients. The monitoring photos are from the clinical trial for medicine-induced hemodialysis. The one-week clinical trial has detached protein allergic reactions from the platelet with mild process, increased the patient's basophils health even though the eosinophil increased. It evidences the Spike 2 protein's immune attacks.</p>
Expression data from 36 KRAS-mutant lung adenocarcinomas from the BATTLE-2 clinical trial.
GEO Series GSE61913. Homo sapiens. 36 samples. Type: Expression profiling by array.
Childhood Cancer Data Initiative (CCDI): Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the NCCR
The goal of this study is to contribute clinical and genomic data from a large institutional cohort of pediatric cancer patients who had tumor genomic profiling between 2013 and 2019 at Dana-Farber/Boston Children's Hospital Cancer and Blood Disorders Center. Clinical data include demographics, diagnosis, stage, and biospecimen associated data. Tumors were sequenced with OncoPanel, a targeted next-generation DNA sequencing panel of up to 447 cancer genes for detection of single-nucleotide variants (SNV), insertions, and deletions, and copy number alterations (CNA), as well as selected intronic regions for up to 60 genes for the detection of structural variants (SV).
Data set from Adamo M, Grasso C, Capodanno D, Rubbio AP, Scandura S, Giannini C, Fiorelli F, Fiorina C, Branca L, Brambilla N, Bedogni F, Petronio AS, Curello S, Tamburino C. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. Am Heart J. 2019 Nov;217:32-41. doi: 10.1016/j.ahj.2019.06.015. Epub 2019 Jul 3. PMID: 31473325.
<p>Data set from Adamo M, Grasso C, Capodanno D, Rubbio AP, Scandura S, Giannini C, Fiorelli F, Fiorina C, Branca L, Brambilla N, Bedogni F, Petronio AS, Curello S, Tamburino C. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry. Am Heart J. 2019 Nov;217:32-41. doi: 10.1016/j.ahj.2019.06.015. Epub 2019 Jul 3. PMID: 31473325.</p> <p> </p> <p>This is the abstract:</p> <p>Limited evidence is available on 5-year clinical outcomes after percutaneous edge-to-edge mitral valve repair.</p> <p><strong>Methods: </strong>The Getting Reduction of mitrAl inSufficiency by Percutaneous clip implantation in ITaly (GRASP-IT) is a multicenter registry including 304 consecutive patients undergoing Mitraclip between October 2008 and October 2013 at 4 Italian centers. Primary end point (all-cause mortality) and secondary end point (all-cause mortality or heart failure [HF] hospitalization) were evaluated up to 5 years and between 1 and 5 years.</p> <p><strong>Results: </strong>Cumulative incidence of the primary and secondary end points at 1, 2, 3, 4, and 5 years were 15.1%, 26.4%, 35.5%, 42.1%, and 47.3% and 29.1%, 41.7%, 49.8%, 56%, and 62.3%, respectively. Landmark analysis between 1 and 5 years showed an incidence of primary and secondary end point of 37.9% and 46.8%, respectively. Five-year event rates were significantly higher in patients with functional ischemic mitral regurgitation (MR) compared to other etiologies. MR recurrence and left ventricular ejection fraction <30% were associated with an increased risk of both primary and secondary end points. EuroSCORE II >5% was associated with an increased risk of 5-year mortality. Ischemic etiology of MR, baseline serum creatinine >1.5 mg/dL, chronic obstructive pulmonary disease, and previous HF hospitalizations were independent predictors of 5-year secondary end point.</p> <p><strong>Conclusions: </strong>At 5-year follow-up after Mitraclip, nearly half of patients died and almost two thirds died or were admitted for HF. MR recurrence, ischemic etiology, high comorbidity burden (ie, EuroSCORE II >5%, chronic obstructive pulmonary disease), and advanced cardiomyopathy (ie, left ventricular ejection fraction <30%, prior HF admission, creatinine >1.5 mg/dL) significantly increase the relative risk of 5-year clinical events.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.